- Global Pharma News & Resources

Press Releases - 2019-11-24

Date Title Company
24-Nov-2019 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference Kazia Therapeutics Limited
24-Nov-2019 DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting DNAtrix, Inc.